Trials / Completed
CompletedNCT00091650
Olanzapine in Patients With Borderline Personality Disorder
Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 15 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The goals of this study are to determine: the safety of olanzapine and any side effects that might be associated with it, how olanzapine compares to placebo, whether olanzapine can help patients with symptoms of Borderline Personality Disorder (BPD), and how much olanzapine should be given to patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olanzapine | |
| DRUG | placebo |
Timeline
- Start date
- 2004-03-01
- Completion
- 2005-11-01
- First posted
- 2004-09-27
- Last updated
- 2006-07-24
Locations
39 sites across 9 countries: United States, Belgium, France, Germany, Norway, Portugal, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00091650. Inclusion in this directory is not an endorsement.